MRRS adds "PharmaPoint: Bipolar Disorder – Global Drug Forecast and Market Analysis to 2024" latest studies, published in Nov 2016.

Summary
Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

Scope
– Overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized bipolar disorder market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
– Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the bipolar disorder therapeutics market.
– Pipeline analysis: focus on two late-stage pipeline bipolar disorder drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of off-label treatments.
– Analysis of the current and future market competition in the global bipolar disorder therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Table of Contents
1 Table of Contents 12
1.1 List of Tables 17
1.2 List of Figures 24
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 30
3.2 Classification 34
3.3 Symptoms 40
3.4 Prognosis 41
4 Epidemiology 43
4.1 Disease Background 43
4.2 Risk Factors and Comorbidities 43
4.3 Global Trends 45
4.4 Forecast Methodology 47
4.4.1 Sources Used 53
4.4.2 Sources Not Used 56
4.4.3 Forecast Assumptions and Methods 56
4.5 Epidemiological Forecast of Bipolar Disorder (2014-2024) 60
4.5.1 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder 60
4.5.2 12-Month Total Prevalent Cases of Bipolar I 61
4.5.3 12-Month Total Prevalent Cases of Bipolar II 63
4.5.4 12-Month Total Prevalent Cases of Cyclothymic Disorder 65
4.5.5 Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder 67
4.5.6 Age-Specific 12-Month Total Prevalent Cases of Bipolar I 68
4.5.7 Age-Specific 12-Month Total Prevalent Cases of Bipolar II 70
4.5.8 Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder 72
4.5.9 Sex-Specific 12-Month Total Prevalent Cases of Bipolar I 74
4.5.10 Sex-Specific 12-Month Total Prevalent Cases of Bipolar II 76
4.5.11 Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder 78
4.5.12 Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder 80...

List of Tables and Figures
Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM 37
Table 2: DSM-V Bipolar Disorder Specifiers 39
Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder 41
Table 4: Risk Factors and Comorbidities for Bipolar Disorder 44
Table 5: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder I Table 6: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder I Table 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder II Table 8: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder II Table 9: 8MM, Sources Used to Forecast 12-Month Total Prevalent Cases of Cyclothymic Disorder Table 10: 8MM, Sources Used to Forecast Lifetime Total Prevalent Cases of Cyclothymic Disorder Table 11: 8MM, 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages ≥13 Years, N (Row %), 2014 61...

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/pharmapoint-bipolar-disorder-global-drug-forecast-and-market-analysis-to-2024

Ask a sample or any futher questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/